A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs is a phase 1/2 interventional study registered as NCT06228326 by Krystal Biotech, Inc., with 250 participants planned, started 2024-04-17 and due to reach its primary completion in 2027-02. Interventions recorded: KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel. Conditions listed: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer. No results are recorded here; the registry entry is the source.